Clinical Trial Update: Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) [Phase 2]

View source ↗

Summary

Phase 2 trial update for selpercatinib in RET fusion differentiated thyroid cancer is currently recruiting (RAISE trial).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• RETEVMO (selpercatinib)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Differentiated Thyroid Cancer, Pediatric Cancer | Phase 2 | Status: RECRUITING